Darunavir is in a class of drugs called protease inhibitors. It works by diminishing the measure of HIV in the blood. In spite of the fact that darunavir doesn’t fix HIV, it might diminish your opportunity of creating (AIDS) and HIV-related ailments like genuine diseases or malignant growth.
Oral Suspension: 100 mg/mL
Tablets: 75 mg, 150 mg, 600 mg, 800 mg
Fixed-Dose Combination Tablets:
[Prezcobix] Darunavir 800 mg/cobicistat 150 mg
[Symtuza] Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg
When utilizing fixed-portion mix (FDC) tablets, allude to different segments of the Drug Appendix for data about the individual parts of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.
Note: Darunavir (DRV) ought not be utilized without a pharmacokinetic (PK) enhancer (boosting specialist). Ritonavir (RTV) might be utilized as the boosting specialist in kids and grown-ups. Cobicistat (COBI) might be utilized as a boosting specialist with DRV in youngsters gauging ≥40 kg and in grown-ups.
DRV isn’t endorsed for use in youngsters/babies.
Matured <3 Years:
Try not to utilize DRV in kids matured <3 years or gauging ≤10 kg. In adolescent rodents, DRV caused spasms and demise; these occasions have been credited to adolescence of the blood–mind hindrance and liver metabolic pathways.
Matured ≥3 Years to <12 Years:
Dosing suggestions in the table beneath are for kids matured ≥3 years to <12 years and gauging ≥10 kg who are antiretroviral treatment (ART)- guileless or treatment-experienced and with or without opposition testing results that show that they have in any event one change that is related with DRV obstruction.
Twice Daily Darunavir and Ritonavir Doses for Children Aged 3 Years to <12 Years and Weighing ≥10 kg
Weight Dose (Twice Daily with Food)a
10 kg to <11 kgb DRV 200 mg (2.0 mL) in addition to RTV 32 mg (0.4 mL)
11 kg to <12 kgb DRV 220 mg (2.2 mL) in addition to RTV 32 mg (0.4 mL)c
12 kg to <13 kgb DRV 240 mg (2.4 mL) in addition to RTV 40 mg (0.5 mL)c
13 kg to <14 kgb DRV 260 mg (2.6 mL) in addition to RTV 40 mg (0.5 mL)c
14 kg to <15 kg DRV 280 mg (2.8 mL) in addition to RTV 48 mg (0.6 mL)c
15 kg to <30 kg DRV 375 mg (mix of tablets or 3.8 mL)d plus RTV 48 mg (0.6 mL)d
30 kg to <40 kg DRV 450 mg (mix of tablets or 4.6 mL)d,e plus RTV (100 mg tablet or powder or 1.25 mL)b
≥40 kg DRV 600 mg (tablet or 6 mL) in addition to RTV 100 mg (tablet or 1.25 mL)
Kid and Adolescent (Aged ≥12 Years and Weighing ≥30 to <40 kg) Dose for Treatment-Naive or Treatment-Experienced Patients With or Without in any event One Mutation Associated With Darunavir Resistance:
DRV 450 mg (utilizing a mix of tablets) in addition to RTV 100 mg, both twice every day with food
Kid and Adolescent (Aged ≥12 years and Weighing ≥40 kg)e and Adult Dose for Treatment-Naive or Treatment-Experienced Patients without any Mutations Associated With Darunavir Resistance
DRV 800 mg (utilizing a tablet or mix of tablets) in addition to RTV 100 mg once every day with food
Kid and Adolescent (Weighing ≥40 kg) and Adult Dose for Treatment-Naive or Treatment-Experienced Patients without any Mutations Associated with Darunavir Resistance
DRV 800 mg (tablet) in addition to COBIf 150 mg (tablet) or the coformulation Prezcobix once every day with food
Kid and Adolescent (Weighing ≥40 kg) and Adult Dose for Treatment-Experienced Patients with in any event One Mutation Associated with Darunavir Resistance
DRV 600 mg in addition to RTV 100 mg, both twice every day with food
The utilization of COBI is not recommended with DRV 600 mg twice every day.
Kid and Adolescent (Weighing ≥40 kg) and Adult Dose for Treatment-Naive or Treatment-
Experienced Patients without any Mutations Associated with Darunavir Resistance:
One tablet once every day with food
[Symtuza] Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (TAF)
Youngster and Adolescent (Weighing ≥40 kg) and Adult Dose:
One tablet once day by day with food in ARV-guileless patients or in patients who have been virologically stifled (HIV RNA <50 duplicates/mL) for in any event a half year with no realized transformations related with protection from DRV or tenofovir.
Skin rash, including Stevens-Johnson condition and erythema multiforme
Looseness of the bowels, sickness
Hyperlipidemia, transaminase rise, hyperglycemia
Once-every day DRV isn’t for the most part suggested for use in kids matured <12 years or gauging <40 kg. Dosing gauges for these patients depended on restricted information, and restricted clinical experience exists with this dosing plan for this age bunch.
Once-every day DRV should not be used if any of the accompanying opposition related transformations is available: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, or L89V.
DRV should be directed with food, which builds DRV plasma focuses by 30%.
DRV contains a sulfonamide moiety. Use DRV with alert in patients with known sulfonamide sensitivities.
Pediatric dosing requires coadministration of tablets of various qualities to accomplish the suggested portion for each weight band. It is imperative to give cautious directions to guardians while suggesting a blend of various strength tablets.
Store DRV tablets and oral suspension at room temperature (25ºC or 77ºF). The suspension should be shaken well prior to dosing.
Screen patients for hepatitis B infection (HBV) contamination prior to utilizing fixed-portion mix (FDC) tablets that contain emtricitabine (FTC) or tenofovir alafenamide (TAF). Serious intense intensification of HBV contamination can happen when FTC or TAF are stopped; subsequently, liver capacity ought to be checked for a while after patients with HBV disease quit taking FTC or TAF.
Cytochrome P450 3A4 substrate and inhibitor.
Darunavir Dosing in Patients with Hepatic Impairment
DRV is principally utilized by the liver. Alert ought to be utilized while regulating DRV to patients with hepatic impedance. DRV is not recommended in patients with serious hepatic disability.
Darunavir Dosing in Patients with Renal Impairment
No DRV portion change is needed in patients with moderate renal hindrance (creatinine clearance 30–60 mL/min).
The FDC Symtuza is not recommended for use in patients with an expected CrCl <30 mL/min.
a Once-day by day dosing of DRV is endorsed by the Food and Drug Administration (FDA), yet the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) doesn’t by and large suggest utilizing this dosing plan for kids (see Frequency of Administration beneath).
b Note that the portion in kids gauging 10–15 kg is DRV 20 mg/kg in addition to RTV 3 mg/kg of body weight per portion, which is higher than the weight-changed portion in kids with higher loads.
c RTV 80 g/mL oral arrangement.
d The volumes for the 375-mg and 450-mg DRV portions are adjusted for suspension-portion comfort.
e Some Panel individuals suggest utilizing the FDA-endorsed portion of once-day by day DRV 675 mg (managed utilizing a mix of tablets) in addition to RTV 100 mg once day by day for young people gauging ≥30 kg to <40 kg (see Table B underneath).
f See the Cobicistat section for significant data about harmfulness, drug collaborations, and observing in patients who get COBI.